journal article·2023-12Open access

Heterodimeric Protein Surface‐Coupling Platform: Immobilization of Conformation Switchable and Functional αIIbβ3 Integrin

Miguel A. D. Neves, Sladjana Slavkovic, Yiming Wang, Yfke Pasman, Aron A. Shoara, Reid C. Gallant, Guangheng Zhu, Pasquale Benvenuto, Philip E. Johnson, Michael Thompson, Heyu Ni

Advanced Materials Interfaces· Volume 10· Issue 35

Abstract

Abstract Many biotechnologies require direct contact between biomolecules and (semi)solid substrates. However, little information is available regarding site‐directed covalent surface immobilization of heterodimeric proteins. Integrins are heterodimeric, conformationally dependent membrane adhesion‐receptors, which are important in the (patho)biology of almost all human diseases. In this study, a biomimetic‐platform is developed for covalent and site‐directed immobilization of oriented integrin heterodimers onto most hydroxyl bearing surfaces, herein demonstrated on both glass‐slides and silica‐particles. This platform consists of a self‐assembled monolayer, upon which C‐terminal modified αIIbβ3 integrin extracellular domains are oriented and covalently anchored. As with cell surface integrins, the conformation of immobilized αIIbβ3 is switchable and can be modulated to the active ligand‐binding conformation by divalent cations. Furthermore, the αIIbβ3‐coupled silica particles display platelet‐mimetic hemostat function and co‐aggregate with platelets from both wild‐type and fibrinogen/von Willebrand factor double deficient mice, facilitating αIIbβ3‐non‐classical ligand discoveries. This work provides a biomaterial platform for functional multimeric protein‐substrate coupling, which should have broad impact on multiple fields of biology, biotechnology, and clinical diagnosis/therapy.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Cell Adhesion Molecules Research · Monoclonal and Polyclonal Antibodies Research · Platelet Disorders and Treatments

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Laboratory Medicine and Pathobiology University of Toronto Toronto ON M5S1A8 Canada

Department of Laboratory Medicine Keenan Research Centre for Biomedical Science St. Michael's Hospital Unity Health Toronto Toronto M5B1W8 Canada

Canadian Blood Services Centre for Innovation Toronto ON M5V1W8 Canada

Toronto Platelet Immunobiology Group University of Toronto Toronto ON M5V1W8 Canada

CCOA Therapeutics Inc. Toronto ON M5B1T8 Canada

Department of Physical and Environmental Sciences University of Toronto Scarborough Toronto ON M1C1A4 Canada

Department of Chemistry York University Toronto ON M3J1P3 Canada

Department of Chemistry University of Toronto Toronto ON M5S3H6 Canada

Funding

Canada Foundation for Innovation · Canadian Blood Services · St. Michael's Hospital Foundation

References (70)

Show source-provided references
1. 10.1021/cr950235710.1021/cr9502357 ↗
2. 10.1021/cr030078910.1021/cr0300789 ↗
3. 10.1039/c0cs00139b10.1039/c0cs00139b ↗
4. 10.1021/la500745p10.1021/la500745p ↗
5. 10.1016/j.jcis.2014.09.02510.1016/j.jcis.2014.09.025 ↗
6. 10.1021/la403823310.1021/la4038233 ↗
7. 10.1021/acs.langmuir.5b0081210.1021/acs.langmuir.5b00812 ↗
8. 10.1021/acs.analchem.5b0401010.1021/acs.analchem.5b04010 ↗
9. 10.1039/C8RA07462C10.1039/C8RA07462C ↗
10. 10.1016/S0927-7765(99)00004-110.1016/S0927-7765(99)00004-1 ↗
11. 10.1016/j.tibs.2020.09.00110.1016/j.tibs.2020.09.001 ↗
12. 10.1016/S0092-8674(02)00971-610.1016/S0092-8674(02)00971-6 ↗
13. 10.1146/annurev.immunol.25.022106.14161810.1146/annurev.immunol.25.022106.141618 ↗
14. 10.5483/BMBRep.2014.47.12.24110.5483/BMBRep.2014.47.12.241 ↗
15. 10.1182/blood.201900231410.1182/blood.2019002314 ↗
16. 10.1242/jcs.0309810.1242/jcs.03098 ↗
17. 10.1186/s12959-016-0100-610.1186/s12959-016-0100-6 ↗
18. 10.1038/nrd.2015.1010.1038/nrd.2015.10 ↗
19. 10.1038/nrd119810.1038/nrd1198 ↗
20. 10.1038/s41467-019-13928-210.1038/s41467-019-13928-2 ↗
21. 10.1074/jbc.273.14.798110.1074/jbc.273.14.7981 ↗
22. 10.1038/s41563-019-0323-610.1038/s41563-019-0323-6 ↗
23. 10.1055/s-0037-161624110.1055/s-0037-1616241 ↗
24. 10.1080/10408363.2016.120000810.1080/10408363.2016.1200008 ↗
25. 10.1038/nm.251510.1038/nm.2515 ↗
26. 10.1161/CIR.000000000000075710.1161/CIR.0000000000000757 ↗
27. 10.1182/blood-2003-03-085010.1182/blood-2003-03-0850 ↗
28. 10.1172/JCI989610.1172/JCI9896 ↗
29. 10.1111/j.1538-7836.2006.02116.x10.1111/j.1538-7836.2006.02116.x ↗
30. 10.1182/blood-2017-05-74318710.1182/blood-2017-05-743187 ↗
31. 10.1016/j.apsusc.2019.14521010.1016/j.apsusc.2019.145210 ↗
32. 10.1038/8756910.1038/87569 ↗
33. 10.1016/j.matbio.2005.12.00110.1016/j.matbio.2005.12.001 ↗
34. 10.1016/j.molcel.2008.11.01810.1016/j.molcel.2008.11.018 ↗
35. 10.1021/la503439g10.1021/la503439g ↗
36. A. V.Naumkin A.Kraut-Vass S. W.Gaarenstroom C. J.Powell NIST X-ray Photoelectron Spectroscopy Database NIST Standard Reference Database 20 Version 4.1 2012.
37. Ratner B. D. · 2013
38. 10.1016/j.jcis.2006.03.04510.1016/j.jcis.2006.03.045 ↗
39. 10.1182/blood-2016-07-72940010.1182/blood-2016-07-729400 ↗
40. Gingras A. R. · 2013
41. 10.1016/j.colsurfb.2015.02.01610.1016/j.colsurfb.2015.02.016 ↗
42. 10.1038/s41467-018-05806-010.1038/s41467-018-05806-0 ↗
43. 10.1080/0953710080223849410.1080/09537100802238494 ↗
44. 10.1016/j.biochi.2017.01.01010.1016/j.biochi.2017.01.010 ↗
45. 10.1021/bi100985810.1021/bi1009858 ↗
46. 10.3390/pharmaceutics1408161310.3390/pharmaceutics14081613 ↗
47. 10.1039/C2TB00019A10.1039/C2TB00019A ↗
48. 10.1016/j.memsci.2016.07.04010.1016/j.memsci.2016.07.040 ↗
49. 10.1016/j.memsci.2019.11729910.1016/j.memsci.2019.117299 ↗
50. 10.1039/C5CS00579E10.1039/C5CS00579E ↗
51. 10.1039/D1BM01580J10.1039/D1BM01580J ↗
52. 10.1039/C7RA05524B10.1039/C7RA05524B ↗
53. 10.1007/s40846-015-0029-410.1007/s40846-015-0029-4 ↗
54. 10.1002/jbm.a.3036510.1002/jbm.a.30365 ↗
55. 10.1039/C5TB01582K10.1039/C5TB01582K ↗
56. 10.1016/j.talanta.2011.04.00810.1016/j.talanta.2011.04.008 ↗
57. 10.1182/blood.V61.1.140.14010.1182/blood.V61.1.140.140 ↗
58. 10.1046/j.1365-2141.1996.445980.x10.1046/j.1365-2141.1996.445980.x ↗
59. 10.1111/jth.1357910.1111/jth.13579 ↗
60. 10.1016/j.biomaterials.2012.09.07410.1016/j.biomaterials.2012.09.074 ↗
61. 10.1002/adma.20120060710.1002/adma.201200607 ↗
62. 10.1038/s41568-018-0038-z10.1038/s41568-018-0038-z ↗
63. 10.1177/088532822096515010.1177/0885328220965150 ↗
64. 10.1002/jbm.b.3431010.1002/jbm.b.34310 ↗
65. 10.1186/s13045-017-0413-310.1186/s13045-017-0413-3 ↗
66. 10.1038/ncomms873710.1038/ncomms8737 ↗
67. 10.1097/MOH.000000000000044710.1097/MOH.0000000000000447 ↗
68. 10.1016/j.bios.2015.05.03810.1016/j.bios.2015.05.038 ↗
69. US Food and Drug Administration Guidance for Industry: Q2B Validation of Analytical Procedures: Methodology http://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM128049.pdf (accessed: Novermber 1996).
70. Miller J. N. · 2010